miR-223-3p regulating the occurrence and development of liver cancer cells by targeting FAT1 gene

Objective To explore the mechanism of miR-223-3p regulating the occurrence and development of liver cancer cells by targeting FAT1 gene. Methods Bioinformatics analysis was used to analyze the differentially expressed genes in liver cancer tissue chips. Forty-eight cases of liver cancer tissues and corresponding adjacent tissues were selected, and qRT-PCR was used to detect the expression of miR-223-3p and FAT1mRNA in tissues. Wound healing assay was used to detect the migration ability of liver cancer cells. Transwell assay was used to detect cells invasion ability. Dual-luciferase assay was used to detect the targeting relationship between miR-223-3p and FAT1. Western blot was used to detect the protein expression of EMT-related markers, E-cadherin and Vimentin. Results FAT1 was highly expressed in liver cancer tissues and cells, while miR-223-3p was lowly expressed. Silencing FAT1 could inhibite the proliferation, migration, invasion and EMT of liver cancer cells. miR-223-3p targeted down-regulated the expression of FAT1, and inhibited the proliferation, migration, invasion and EMT of liver cancer cells by targeting FAT1. Conclusion miR-223-3p regulates the occurrence and development of liver cancer cells by targeted down-regulating the expression of FAT1

In vivo therapeutic potential of Inula racemosa in hepatic ischemia–reperfusion injury following orthotopic liver transplantation in male albino rats

Abstract Hepatic ischemia–reperfusion (I/R) injury mainly occurs following hepatic resection and liver transplantation and cause severe liver damage, organ injuries, and dysfunction. Pro-inflammatory cytokines that promote injury are released when kupffer cell activates after getting induced by I/R. Repercussions of oxidative stress and cardiac function against isoproterenol based myocardial infarction are caused by flavonol glycosides which are found in high concentrations in Inula racemosa (Ir).The root was deemed to have analgesic and anti-inflammatory effects, and no report has been published about the liver-protective activity against hepatic I/R. Therefore, the present study was aimed to understand the therapeutic impact of Ir in hepatic I/R injury. Male albino, Wistar strain rats were used and were grouped into four total phenolic content, free radical scavenging activity and serum enzymes were determined. Histopathological and immunohistochemical analysis were also carried out. Inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin (IL-6) and protein expression of p53, bax, and bcl-2 were determined. The administration of extracts of Ir significantly increased total phenolic and free radical scavenging activity. Altered cellular morphology, cytokines and aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH) were returned to near normal level. IL-6 and TNF-α levels were reduced more than 25% following treatment. Also, the protein expression of p53, bax, and bcl-2 were also returned to near normal level. Taking all these data together, it is suggested that the extracts of Ir may be a potential therapeutic agent for providing several beneficial effects in hepatic I/R injury

Post-Operative Complications in Living Liver Donors: A Single-Center Experience in China.

The gap between the growing demand for available organs and the cadaveric organs facilitates the adoption of living donor liver transplantation. We retrospectively identified and evaluated the post-operative complications as per the modified Clavien classification system in 152 living liver donors at at the First Affiliated Hospital, College of Medicine, Zhejiang University between December, 2006 and June, 2014. Post-operative complications were observed in 61 patients (40.1%) in the present study, but no mortality was reported. Complications developed in 58 (40.0%) right, 1 (33.3%) left, and 2 (66.7%) lateral left hepatectomy donors. The prevalence of re-operation was 1.3%. Grade I and II complications were observed in 38 (25.0%) and 11 (7.2%) donors, respectively. Grade IIIa complications developed in 9 (5.9%) donors and only 3 (2.0%) patients reported grade IIIb complications. The most common complication was pleural effusion that occurred in 31 (20.4%) donors. No significant prognostic baseline factor was identified in this study. In conclusion, living donors experienced various complications, which were usually mild and had a good prognosis

Exclusion criteria for the donors.

<p>Exclusion criteria for the donors.</p

Comparison of pre-operative and operative variables between different grades of complications.

<p>Grade IIIa and IIIb complications are combined as one variable.</p><p>ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase; BMI: Body Mass Index; INR: International Normalized Ratio; LH: Left Hepatectomy; LLH: Lateral Left Hepatectomy; LOS: Length of Hospital Stay; MHV: Middle Hepatic Vein; RH: Right Hepatectomy.</p><p>Comparison of pre-operative and operative variables between different grades of complications.</p

Post-operative biochemical parameter values in living donors after procedure.

<p><b>A:</b> TB value returned to normal within the first week after procedure, but AST and ALT recovered after 7 days. <b>B:</b> PT value peaked on POD 1 and returned to normal within the first week. <b>C:</b> INR descended on the first 3 days after LDLT, but markedly increased and peaked at 4^th and 5^th day.</p

Pre-operative and operative characteristics of 152 living liver donors.

<p>BMI: Body Mass Index; MHV: Middle Hepatic Vein; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; INR: International Normalized Ratio.</p><p>Pre-operative and operative characteristics of 152 living liver donors.</p

Additional file 2: Figure S2. of Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio

Differentiate value of PLR for patients exceeding the Hangzhou criteria. There was no significant difference in RFS for patients exceeding the Hangzhou criteria after stratification by different PLR cut-off values (90, 100, 110, 130, and 140). (TIF 52 kb

Additional file 1: Figure S1. of Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio

RFS of patients fulfilling the Milan criteria stratified by different pre-transplant PLR values. For patients who fulfilled the Milan criteria, the RFS was comparable after stratification by different PLR cut-off values (90, 100, 110, 130, and 140). (TIF 738 kb